What does 5-Amino-1MQ do?

The supplied evidence describes 5-Amino-1MQ as a small molecule, not a peptide. It is presented as an NNMT inhibitor studied in obese mice, where the reported findings included reduced body weight and fat mass without a reduction in food intake. Human clinical trial evidence was not reported in the provided source.

How does 5-Amino-1MQ work?

The proposed mechanism centers on inhibition of nicotinamide N-methyltransferase. In the source description, NNMT activity is connected to nicotinamide, SAM, NAD+ and adipocyte energy handling. Mouse research cited by the source reported higher intracellular NAD+ and SAM with NNMT inhibition, but the source also frames human effects as unproven.

Is 5-Amino-1MQ FDA approved?

No. The supplied source lists 5-Amino-1MQ as not FDA approved and categorizes its status as preclinical research.

What side effects are reported for 5-Amino-1MQ?

Reported effects in the source include mild headache during initial dosing, nausea, increased alertness or jitteriness, rare insomnia and rare elevated blood pressure. These are source-reported observations, not a quantified safety profile from human trials.

What dose information is reported for 5-Amino-1MQ?

The source gives a community-reported common amount of 50-75 mg daily, with a listed range of 50-100 mg daily and once-daily morning timing. It also separately lists 20 mg/kg/day in mice for research context.

This entry is not a peptide · It is included because this compound is commonly discussed alongside peptide research.

Weight Loss Preclinical - animal studies only

5-Amino-1MQ

Also known as: 5-amino-1-methylquinolinium, NNMT Inhibitor

At a glance

PeptiGuide dataset · reviewed Jul 2026

What it is

A non-peptide NNMT inhibitor researched in preclinical fat-metabolism models.

Status

Preclinical

Evidence level: animal studies

Typical dose

50–75mg

Subcutaneous injection or oral

Researched for

Fat metabolism, cellular energy, body composition

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

5-Amino-1MQ is identified by the source as a small molecule rather than a .
It is described as an NNMT inhibitor researched for fat metabolism, cellular energy and body composition.
The evidence supplied is , with animal and cell-study support and no published human trials reported.
Community dose entries list 50-75 mg daily, usually once in the morning, with oral or routes noted.

How it's thought to work

5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.

What the research shows

Where the research stands

The supplied source highlights work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research; no published human trials reported in the supplied source Not FDA approved

Typical dosing

CommunityCommunity dataset

50–75 mg

daily

50 mgfull range seen100 mg

Community-reported dosing is presented as observational source data only. The same source describes weight-based community ranges of 50-75 mg under 150 lb, 75 mg from 150-200 lb, and 75-100 mg above 200 lb. · 4-6 weeks on, 2-4 weeks off

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

20 mg/kg/day (mice)

PMC Research - NNMT inhibitor obesity study

Animal study doses may not translate directly to humans.

Duration: 4-6 weeks (cycling recommended)
Administration: Subcutaneous injection or oral

Timing & administration

Best time to take

Morning, fasted

Once daily

Food recommendation

With or without food

Why this timing?

The source favors morning timing because it is presented as more consistent with metabolic activity patterns and less likely to interfere with sleep.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Mild headache
Nausea
Increased alertness or jitteriness
Insomnia
Elevated blood pressure

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on 5‑Amino‑1MQ

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

5-Amino-1MQ

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows